BioNTech Comes Forth With Stunning Admission About Jab Efficacy In United States

According to many recent reports and statements released from Pfizer, Moderna, and similar pharma giants directly involved with the creation, distribution and marketing of the COVID vaccines – that’s what they actually did. And only that – MARKETING.

Science, research, and helping humanity in health and prosperity weren’t even in the picture.

Join The True Defender Telegram Chanel Here: https://t.me/TheTrueDefender

The most recent publishing from BioNTech was a SEC – Securities and Exchange Comission, which revealed ‘and astonishing admission regarding the concerns over the efficacy or safety of the COVID shot made by the company.’

To be more specific, the company has revealed to investors in the filing that they may not be able to acquire or maintain any sort of “permanent regulatory approval” due to issues related to efficacy or safety.

“On March 30th, BioNTech released a Form 20-F detailing their annual report for the fiscal year ending on December 31st, 2021. For those unaware, a Form 20-F is a specific SEC form utilized by foreign companies where 50% or less of their shares are held by U.S. citizens and can be traded within the American markets.

Among the information contained within the SEC filing is a section aptly dubbed “Risk Factors,” which spells out all the variables that could result in some not-so-favorable scenarios for investors that could cause stock prices to plummet.

When going to page six, section “D,” within the risk factors portion of the filing, BioNTech plainly stated that one of the critical risk factors relates to their number one product – the COVID shot – in the realm of “efficacy or safety” that could disrupt “regulatory approval.”

“We may not be able to demonstrate sufficient efficacy or safety of our COVID-19 vaccine and/or variant-specific formulations to obtain permanent regulatory approval in the United States, the United Kingdom, the European Union, or other countries where it has been authorized for emergency use or granted conditional marketing approval.”

Source

BioNTech Investors Red Voice Media

Leave a Reply

Your email address will not be published.